{"id":1488,"text":"Women receiving treatment for breast cancer commonly ingest herbal medicines.","label":[[0,5,"Sex"],[30,43,"Pathology"]],"Comments":[]}
{"id":1489,"text":"Little is known about the potential for herb-drug interactions in this population.","label":[],"Comments":[]}
{"id":1490,"text":"The aim of this study is to investigate the effect of ginkgo biloba co-administration on the pharmacokinetics of tamoxifen, anastrozole and letrozole.","label":[[54,67,"Herb name"],[113,122,"Drug"],[124,135,"Drug"],[140,149,"Drug"]],"Comments":[]}
{"id":1491,"text":"This was a prospective open-label cross-over study in 60 women with early stage breast cancer taking either tamoxifen, anastrozole or letrozole (n=20\/group).","label":[[11,50,"Study"],[54,62,"Cohort"],[68,93,"Pathology"],[108,117,"Drug"],[119,130,"Drug"],[134,143,"Drug"]],"Comments":[]}
{"id":1492,"text":"Participants received ginkgo biloba (EGb 761) for 3 weeks (120 mg twice daily).","label":[[22,45,"Herb name"],[50,57,"Duration"],[59,65,"Amount"],[66,77,"Frequency"]],"Comments":[]}
{"id":1493,"text":"Trough concentrations of drugs were measured before and after ginkgo biloba treatment using LC-MS\/MS.","label":[[62,75,"Herb name"]],"Comments":[]}
{"id":1494,"text":"Toxicities were graded according to National Cancer Institute Common Terminology Criteria for Adverse Events.","label":[[94,108,"Pathology"]],"Comments":[]}
{"id":1495,"text":"Trough concentrations before and after treatment with ginkgo biloba were not significantly different for tamoxifen (93.5 ± 29.0, 86.5 ± 25.3 ng\/mL; p=0.16), letrozole (91.1 ± 50.4, 89.6 ± 52.14 ng\/mL; p=0.60) or anastrozole (29.1 ± 8.6, 29.1 ± 7.6 ng\/mL; p=0.97).","label":[[54,67,"Herb part"],[105,114,"Drug"],[157,166,"Drug"],[212,223,"Drug"]],"Comments":[]}
{"id":1496,"text":"Ginkgo biloba was well tolerated, with no difference in toxicity during ginkgo biloba.","label":[[0,13,"Herb name"],[72,85,"Herb name"]],"Comments":[]}
{"id":1497,"text":"Co-administration of ginkgo biloba does not significantly affect the pharmacokinetics of tamoxifen, anastrozole or letrozole.","label":[[21,34,"Herb name"],[89,98,"Drug"],[100,111,"Drug"],[115,124,"Drug"]],"Comments":[]}
{"id":1498,"text":"There was no difference in the toxicity profile of hormone therapy with ginkgo biloba use in women with early stage breast cancer.","label":[[51,66,"Drug"],[72,85,"Herb name"],[93,98,"Sex"],[104,129,"Pathology"]],"Comments":[]}
{"id":1499,"text":"Complementary and alternative medicines (CAM) are widely used by a large proportion of cancer patients (mean 36%, range up to 80%) (Sparreboom et al.","label":[[87,93,"Pathology"]],"Comments":[]}
{"id":1500,"text":"The herbal medicine ginkgo biloba is commonly used in the community (Sparreboom et al.","label":[[11,26,"Herb name"]],"Comments":[]}
{"id":1501,"text":"No published RCT have assessed the effects of ginkgo biloba on anti-cancer hormone pharmacokinetics (Sparreboom et al.","label":[[13,16,"Study"],[46,59,"Herb name"]],"Comments":[]}
{"id":1502,"text":"The aim of this study is to investigate the effect of ginkgo biloba co-administration on the pharmacokinetics of tamoxifen, anastrozole and letrozole in women with early stage breast cancer.","label":[[54,67,"Herb name"],[113,122,"Drug"],[124,135,"Drug"],[140,149,"Drug"],[153,158,"Sex"],[164,189,"Pathology"]],"Comments":[]}
{"id":1503,"text":"Anastrozole, D12-anastrozole, letrozole, D4-letrozole, tamoxifen and D5-tamoxifen were purchased from Research Chemical North York (Ontario, Canada).","label":[[0,11,"Drug"],[13,28,"Drug"],[30,39,"Drug"],[41,53,"Drug"],[55,64,"Drug"],[69,81,"Drug"]],"Comments":[]}
{"id":1504,"text":"Methanol was purchased from Fisher Scientific (New Jersey USA).","label":[],"Comments":[]}
{"id":1505,"text":"Orthophosphoric Acid (85%), hydrochloric acid (AnalaR) and ammonia (AR) were purchased from BDH, Biolab (Scoresby, VIC, Australia).","label":[],"Comments":[]}
{"id":1506,"text":"Formic Acid (AR grade) was purchased from Merck (Kilsyth, VIC, Australia).","label":[],"Comments":[]}
{"id":1507,"text":"Strata-X-C 33Hm Cation Mixed-Mode Polymeric Sorbent solid phase extraction cartridges (200 mg \/3 mL) were obtained from Phenomenex (Torrana, CA, USA).","label":[],"Comments":[]}
{"id":1508,"text":"This was a prospective open-label cross-over study in 60 women with early stage breast cancer taking tamoxifen, anastrozole or letrozole (n=20\/group).","label":[[11,50,"Study"],[54,62,"Cohort"],[68,93,"Pathology"],[101,110,"Drug"],[112,123,"Drug"],[127,136,"Drug"]],"Comments":[]}
{"id":1509,"text":"Women were being treated at Concord Repatriation General Hospital, Royal Prince Alfred Hospital and Strathfield Breast Centre in Sydney, Australia.","label":[[0,5,"Sex"]],"Comments":[]}
{"id":1510,"text":"All women had previously completed surgery ± adjuvant chemotherapy for localised breast cancer, and had no evidence of a recurrence of their cancer.","label":[[4,9,"Sex"],[45,66,"Drug"],[71,94,"Pathology"],[141,147,"Pathology"]],"Comments":[]}
{"id":1511,"text":"They had to have been on a stable dose of the hormone for a minimum of two months, to ensure steady-state had been achieved.","label":[[54,81,"Duration"]],"Comments":[]}
{"id":1512,"text":"The study exclusion criteria included: use of trazodone, monoamine oxidase inhibitors, thiazide diuretics, anticoagulation, or anti-platelet medications other than low-dose aspirin or coumarin\/heparin flushes associated with use of a portacath, and ingestion of ginkgo biloba within 4 weeks of the study commencement.","label":[[46,85,"Drug"],[87,105,"Drug"],[107,122,"Drug"],[127,140,"Drug"],[173,180,"Drug"],[184,192,"Drug"],[193,200,"Drug"],[262,275,"Herb name"],[276,290,"Duration"]],"Comments":[]}
{"id":1513,"text":"At baseline, toxicity data for hormone treatment and ginkgo biloba were collected.","label":[[31,48,"Drug"],[53,66,"Herb name"]],"Comments":[]}
{"id":1514,"text":"Women then commenced an open label standardised extract of ginkgo biloba (EGb 761, 120 mg bd) for a three week period.","label":[[0,5,"Sex"],[24,55,"Extraction process"],[59,81,"Herb name"],[83,89,"Amount"],[94,117,"Duration"]],"Comments":[]}
{"id":1515,"text":"Toxicity data were collected at the end of the dosing interval.","label":[],"Comments":[]}
{"id":1516,"text":"Plasma samples to measure the concentration of the anastrozole, letrozole or tamoxifen were taken to assess trough concentrations of each drug.","label":[[51,62,"Drug"],[64,73,"Drug"],[77,86,"Drug"]],"Comments":[]}
{"id":1517,"text":"The study was approved by the Human Research Ethics Committee of all participating institutions and written informed consent was obtained from all participants.","label":[],"Comments":[]}
{"id":1518,"text":"Blood samples were collected into heparinised collecting tubes by venepuncture.","label":[],"Comments":[]}
{"id":1519,"text":"Samples were centrifuged for 10 min at 4°C and plasma transferred into vials, which were stored at -70°C until analysed.","label":[],"Comments":[]}
{"id":1520,"text":"Sample preparation was based on the publication by (Beer et al.","label":[],"Comments":[]}
{"id":1521,"text":"The chromatographic system consisted of a Waters Acquity® UPLC solvent delivery system and autosampler (Milford MA, USA) and an AB Sciex QTrap 4000 linear quadrupole mass spectrometer (Concord, ON, Canada) equipped with a turbo ion spray (ESI) source.","label":[],"Comments":[]}
{"id":1522,"text":"The mass spectrometer was operated in positive ion mode.","label":[],"Comments":[]}
{"id":1523,"text":"Multiple reaction monitoring (MRM) was performed using specific precursor-to-product ion transitions m\/z.","label":[],"Comments":[]}
{"id":1524,"text":"Chromatographic separation was accomplished on a Restek PFP C The calibration curves for each analyte were linear over the concentration range of 2.5 to 750 ng\/mL.","label":[],"Comments":[]}
{"id":1525,"text":"The lower limit of quantitation for anastrozole and letrozole was 2.5 ng\/mL and 10 ng\/mL for tamoxifen.","label":[[36,47,"Drug"],[52,61,"Drug"],[93,102,"Drug"]],"Comments":[]}
{"id":1526,"text":"The extraction recovery from human plasma was considered acceptable with a mean recovery of greater than 88% for each analyte.","label":[],"Comments":[]}
{"id":1527,"text":"Minimal ionization suppression was observed in both the low concentration and high concentration spiked plasma samples and the variation in matrix effects between the five different sources of plasma was minimal for all analytes over a range of concentrations.","label":[],"Comments":[]}
{"id":1528,"text":"No endogenous peaks were identified in the extracted ion chromatograms that would cause interference with drug quantitation.","label":[],"Comments":[]}
{"id":1529,"text":"The assay performance was assessed over 3 days (4 replicates) at 3 concentration levels.","label":[],"Comments":[]}
{"id":1530,"text":"The relative error for each analyte was less than 9% and the intra-day and inter-day precision (%RSD) was less than 7% for anastrozole, letrozole and tamoxifen.","label":[[123,134,"Drug"],[136,145,"Drug"],[150,159,"Drug"]],"Comments":[]}
{"id":1531,"text":"Steady-state trough concentrations of each drug were compared before and during treatment with ginkgo biloba extract.","label":[[95,116,"Extraction process"]],"Comments":[]}
{"id":1532,"text":"Comparisons were made using a paired t-test.","label":[],"Comments":[]}
{"id":1533,"text":"Toxicities are graded according to National Cancer Institute Common Terminology Criteria for Adverse Events Version 3.0 (NCI CTCAE).","label":[[93,107,"Pathology"]],"Comments":[]}
{"id":1534,"text":"Sixty women with early stage breast cancer participated; 20 were using tamoxifen, letrozole and anastrozole respectively.","label":[[0,11,"Cohort"],[17,42,"Pathology"],[71,80,"Drug"],[82,91,"Drug"],[96,107,"Drug"]],"Comments":[]}
{"id":1535,"text":"The 48 (80%) women who had received adjuvant chemotherapy were a mean of 37 months (range 4–113) from completion of chemotherapy.","label":[[36,57,"Drug"]],"Comments":[]}
{"id":1536,"text":"Twenty four (40%) had received a taxane-containing regimen and 24 (40%) an anthracycline regimen, with 6 (10%) women also being treated with adjuvant Trastuzumab.","label":[[33,39,"Drug"],[75,88,"Drug"],[111,116,"Sex"],[150,161,"Drug"]],"Comments":[]}
{"id":1537,"text":"Twelve (20%) women had not required adjuvant chemotherapy.","label":[[13,18,"Sex"],[36,57,"Drug"]],"Comments":[]}
{"id":1538,"text":"The median age of participants was 57 years (range: 33– 86 years).","label":[[4,65,"Age"]],"Comments":[]}
{"id":1539,"text":"Individual trough concentrations of the anti-estrogenic agents prior to using ginkgo biloba and after 3 weeks of ginkgo biloba treatment are outlined in Figure  Trough concentration of anti-estrogenic agents with and withoutginkgo biloba(GB) treatment.","label":[[40,62,"Drug"],[78,91,"Herb name"],[96,109,"Duration"],[113,126,"Herb name"],[185,207,"Drug"],[224,241,"Herb name"]],"Comments":[]}
{"id":1540,"text":"A) Tamoxifen.","label":[[3,12,"Drug"]],"Comments":[]}
{"id":1541,"text":"B) Letrozole.","label":[[3,12,"Drug"]],"Comments":[]}
{"id":1542,"text":"C) Anastrazole.","label":[[3,14,"Drug"]],"Comments":[]}
{"id":1543,"text":"Pharmacokinetics of tamoxifen, letrozole and anastrozole before and after treatment with                            ginkgo biloba (GB)                         *paired test; data presented as mean ± standard deviation.","label":[[20,29,"Drug"],[31,40,"Drug"],[45,56,"Drug"],[116,134,"Herb name"]],"Comments":[]}
{"id":1544,"text":"Thirty-one of the 60 women reported no side effects.","label":[[18,26,"Cohort"],[39,51,"Pathology"]],"Comments":[]}
{"id":1545,"text":"There were no grade 3 toxicities but two women reported grade 2 toxicities (1 headache, 1 flu-like symptoms).","label":[[78,86,"Pathology"],[90,107,"Pathology"]],"Comments":[]}
{"id":1546,"text":"The most common side effects were headache (n=8), flatulence (n=6), hot flushes (n=5), nausea (n=2) and diarrhoea (n=2).","label":[[16,28,"Pathology"],[34,42,"Pathology"],[50,60,"Pathology"],[68,79,"Pathology"],[87,93,"Pathology"],[104,113,"Pathology"]],"Comments":[]}
{"id":1547,"text":"One woman each complained of appetite loss, dizziness, disturbed dreams, dry skin, flu-like symptoms, pain in extremities and a metallic taste.","label":[[4,9,"Sex"],[29,42,"Pathology"],[44,53,"Pathology"],[55,71,"Pathology"],[73,81,"Pathology"],[83,100,"Pathology"],[102,121,"Pathology"],[128,142,"Pathology"]],"Comments":[]}
{"id":1548,"text":"Although ginkgo biloba is a CAM that is commonly used by cancer patients, there is a lack of information about the impact of ginkgo biloba administration on cancer treatments such as chemotherapy and hormonal treatment.","label":[[9,22,"Herb name"],[57,63,"Pathology"],[125,138,"Herb name"],[157,163,"Pathology"],[183,195,"Drug"],[200,218,"Drug"]],"Comments":[]}
{"id":1549,"text":"This study investigated the interaction between the anti-cancer hormonal agents tamoxifen, anastrozole and letrozole, and a standardised extract of ginkgo biloba (EGb761) in women with breast cancer.","label":[[52,79,"Drug"],[80,89,"Drug"],[91,102,"Drug"],[107,116,"Drug"],[148,170,"Herb name"],[174,179,"Sex"],[185,198,"Pathology"]],"Comments":[]}
{"id":1550,"text":"This patient population was selected as women with breast cancer are reported to use more CAM than other cancer patients, and the majority take tamoxifen, anastrozole or letrozole for a period of 5 years.","label":[[40,45,"Sex"],[51,64,"Pathology"],[105,111,"Pathology"],[144,153,"Drug"],[155,166,"Drug"],[170,179,"Drug"],[186,203,"Duration"]],"Comments":[]}
{"id":1551,"text":"It is therefore critical to know if there is a pharmacokinetic interaction between ginkgo biloba and common anti-cancer hormonal treatment.","label":[[83,96,"Herb name"],[108,138,"Drug"]],"Comments":[]}
{"id":1552,"text":"There are no published controlled trials that have assessed the effects of ginkgo biloba on chemotherapy pharmacokinetics (Sparreboom et al.","label":[[23,40,"Study"],[75,88,"Herb name"]],"Comments":[]}
{"id":1553,"text":"Zadoyan et al.","label":[],"Comments":[]}
{"id":1554,"text":"recently reported a cocktail drug interaction study exploring potential interaction with the ginkgo biloba standardised extract EGb 761 (Zadoyan et al.","label":[[93,135,"Extraction process"]],"Comments":[]}
{"id":1555,"text":"Several large placebo-controlled RCT have found ginkgo biloba to be extremely well tolerated, with no differences in side effects between those receiving ginkgo biloba and those receiving placebo.","label":[[48,61,"Herb name"],[117,129,"Pathology"],[154,167,"Herb name"]],"Comments":[]}
{"id":1556,"text":"In our study the majority of participants reported either no side effects or minor side effects such as headache, flatulence and hot flushes - some of which are likely to have been due to the hormonal treatment rather than the ginkgo biloba.","label":[[61,73,"Pathology"],[83,95,"Pathology"],[104,112,"Pathology"],[114,124,"Pathology"],[129,140,"Pathology"],[192,210,"Drug"],[227,240,"Herb name"]],"Comments":[]}
{"id":1557,"text":"In conclusion, ginkgo biloba (EGb761) co-administration did not significantly affect the pharmacokinetics of tamoxifen, anastrozole or letrozole, and was well tolerated with minimal side effects.","label":[[15,37,"Herb name"],[109,118,"Drug"],[120,131,"Drug"],[135,144,"Drug"],[182,194,"Pathology"]],"Comments":[]}
{"id":1558,"text":"Our results suggest that the co-administration of EGb761 is unlikely to lead to clinically significant interactions for women who are receiving hormonal treatment for breast cancer.","label":[[50,56,"Extraction process"],[120,125,"Sex"],[144,162,"Drug"],[167,180,"Pathology"]],"Comments":[]}
{"id":1559,"text":"A study is in progress evaluating the pharmacokinetic impact of ginkgo biloba on common chemotherapy agents in women receiving adjuvant chemotherapy for early stage breast cancer.","label":[[64,77,"Herb name"],[88,107,"Drug"],[111,116,"Sex"],[153,178,"Pathology"]],"Comments":[]}
{"id":1560,"text":"Competing interests          The authors have declared no conflicts of interests.","label":[],"Comments":[]}
{"id":1561,"text":"Authors’ contributions          JV, AM, HD and SC conceived and designed the study and JV, AM and HD wrote the protocol.","label":[],"Comments":[]}
{"id":1562,"text":"IO, FL, AW, HD, JB, AS, AH, PB recruited patients and IO, FL, AW and HD supervised blood sample collection and data collection.","label":[],"Comments":[]}
{"id":1563,"text":"AR and AM supervised the pharmacokinetic analyses.","label":[],"Comments":[]}
{"id":1564,"text":"AM analysed the pharmacokinetic data.","label":[],"Comments":[]}
{"id":1565,"text":"JV, HD and AM wrote the manuscript.","label":[],"Comments":[]}
{"id":1566,"text":"All authors read and approved the final manuscript.","label":[],"Comments":[]}
{"id":1567,"text":"This work was supported by an American Society of Clinical Oncology (ASCO) Career Development Award awarded to A\/Prof.","label":[[30,38,"Ethnic group"]],"Comments":[]}
{"id":1568,"text":"Vardy and a National Institute of Complementary Medicine project grant.","label":[],"Comments":[]}
{"id":1569,"text":"A\/Prof.","label":[],"Comments":[]}
{"id":1570,"text":"Vardy is supported by a Cancer Institute NSW Clinical Research Fellowship and Dr Olesen was supported by an National Health and Medical Research Council PhD Scholarship.","label":[],"Comments":[]}
{"id":1571,"text":"The authors acknowledge Stacey Richards and John Keledjian from the Australian Racing Forensic Laboratory (Randwick, Australia) who conducted the sample analysis.","label":[[68,78,"Ethnic group"]],"Comments":[]}
